I believe another fundamental difference with Life metrics is they don't measure "central blood pressure". This along with the 15 years of validated data is and always will be the competitive advantage that makes us different. Some nice price action today, all primed up. I"m sure the scouts at Omron are watching this one very closely. They've shelled out big on takeovers in the past, agree it's too early to sell but I think our friend Jackpot is on the money. A bid at 3-4 x market cap would be the re-rate we are looking for. Goodbye penny stock status, hello validated high growth potential tech unicorn.
Add to My Watchlist
What is My Watchlist?
